"Maximum Tolerated Dose" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)
| Descriptor ID |
D020714
|
| MeSH Number(s) |
E05.940.481 G07.690.936.625
|
| Concept/Terms |
Maximum Tolerated Dose- Maximum Tolerated Dose
- Dose, Maximum Tolerated
- Doses, Maximum Tolerated
- Maximum Tolerated Doses
- Tolerated Dose, Maximum
- Tolerated Doses, Maximum
- Maximally Tolerated Dose
- Dose, Maximally Tolerated
- Doses, Maximally Tolerated
- Maximally Tolerated Doses
- Tolerated Dose, Maximally
- Tolerated Doses, Maximally
- Maximal Tolerated Dose
- Dose, Maximal Tolerated
- Doses, Maximal Tolerated
- Maximal Tolerated Doses
- Tolerated Dose, Maximal
- Tolerated Doses, Maximal
|
Below are MeSH descriptors whose meaning is more general than "Maximum Tolerated Dose".
Below are MeSH descriptors whose meaning is more specific than "Maximum Tolerated Dose".
This graph shows the total number of publications written about "Maximum Tolerated Dose" by people in this website by year, and whether "Maximum Tolerated Dose" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 3 | 3 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 2 | 2 |
| 2019 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Maximum Tolerated Dose" by people in Profiles.
-
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial. Lancet Oncol. 2022 08; 23(8):1021-1030.
-
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2021 02 11; 137(6):751-762.
-
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Ann Oncol. 2019 10 01; 30(10):1613-1621.
-
A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol. 2019 08; 154(2):294-301.
-
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. Invest New Drugs. 2019 06; 37(3):461-472.
-
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018 10; 151(1):46-52.
-
Dose Escalation of Total Marrow Irradiation in High-Risk Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017 Jul; 23(7):1110-1116.
-
A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852). Ann Oncol. 2017 03 01; 28(3):505-511.
-
Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy. Clin Cancer Res. 2017 04 15; 23(8):1955-1966.
-
Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. PLoS One. 2016; 11(6):e0156910.